Search research articles
Contact Us
Filters
Showing results (51-60 of 276) with videos related to
Page
of 28
Sort By:
Expert Opinion on Biological Therapy
|
June 12, 2015
Fecal microbiota transplantation for Clostridium difficile infection: back to the future
Guglielmo Borgia, Alberto Enrico Maraolo, Maria Foggia, et al.
Pathogens (Basel, Switzerland)
|
August 6, 2020
Prohibitin 2 is Involved in Parkin-Mediated Mitophagy in Urothelial Cells of Cattle Infected with Bovine Papillomavirus
Francesca De Falco, Ivan Gentile, Pellegrino Cerino, et al.
Expert Opinion on Drug Safety
|
June 1, 2018
Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis
Antonio Riccardo Buonomo, Emanuela Zappulo, Giulio Viceconte, et al.
Diagnostics (Basel, Switzerland)
|
January 21, 2023
The Role of CRP POC Testing in the Fight against Antibiotic Overuse in European Primary Care: Recommendations from a European Expert Panel
Ivan Gentile, Nicola Schiano Moriello, Rogier Hopstaken, et al.
Journal of Clinical Medicine
|
December 11, 2022
Evaluation of Drug Interactions in Patients Treated with DAAs for Hepatitis C Therapy with Comorbidities and Cardiovascular Issues-A Delphi Consensus Project
Claudio Borghi, Alessia Ciancio, Ivan Gentile, et al.
Current Medicinal Chemistry
|
July 10, 2014
ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection
Ivan Gentile, Federico Borgia, Antonio Riccardo Buonomo, et al.
Expert Review of Gastroenterology & Hepatology
|
September 9, 2016
Limiting the access to direct-acting antivirals against HCV: an ethical dilemma
Ivan Gentile, Alberto E Maraolo, Massimo Niola, et al.
Expert Opinion on Investigational Drugs
|
March 27, 2014
MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection
Ivan Gentile, Antonio Riccardo Buonomo, Federico Borgia, et al.
Expert Opinion on Investigational Drugs
|
March 3, 2016
Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development
Ivan Gentile, Riccardo Scotto, Emanuela Zappulo, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research
|
March 18, 2003
Pernicious anemia during IFN-alpha treatment for chronic hepatitis C
Guglielmo Borgia, Laura Reynaud, Ivan Gentile, et al.
Page
of 28
Search research articles
Search
Showing results (51-60 of 276) with videos related to
Sort By:
Page
of 28
Expert Opinion on Biological Therapy
|
June 12, 2015
Fecal microbiota transplantation for Clostridium difficile infection: back to the future
Guglielmo Borgia, Alberto Enrico Maraolo, Maria Foggia, et al.
Pathogens (Basel, Switzerland)
|
August 6, 2020
Prohibitin 2 is Involved in Parkin-Mediated Mitophagy in Urothelial Cells of Cattle Infected with Bovine Papillomavirus
Francesca De Falco, Ivan Gentile, Pellegrino Cerino, et al.
Expert Opinion on Drug Safety
|
June 1, 2018
Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis
Antonio Riccardo Buonomo, Emanuela Zappulo, Giulio Viceconte, et al.
Diagnostics (Basel, Switzerland)
|
January 21, 2023
The Role of CRP POC Testing in the Fight against Antibiotic Overuse in European Primary Care: Recommendations from a European Expert Panel
Ivan Gentile, Nicola Schiano Moriello, Rogier Hopstaken, et al.
Journal of Clinical Medicine
|
December 11, 2022
Evaluation of Drug Interactions in Patients Treated with DAAs for Hepatitis C Therapy with Comorbidities and Cardiovascular Issues-A Delphi Consensus Project
Claudio Borghi, Alessia Ciancio, Ivan Gentile, et al.
Current Medicinal Chemistry
|
July 10, 2014
ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection
Ivan Gentile, Federico Borgia, Antonio Riccardo Buonomo, et al.
Expert Review of Gastroenterology & Hepatology
|
September 9, 2016
Limiting the access to direct-acting antivirals against HCV: an ethical dilemma
Ivan Gentile, Alberto E Maraolo, Massimo Niola, et al.
Expert Opinion on Investigational Drugs
|
March 27, 2014
MK-5172 : a second-generation protease inhibitor for the treatment of hepatitis C virus infection
Ivan Gentile, Antonio Riccardo Buonomo, Federico Borgia, et al.
Expert Opinion on Investigational Drugs
|
March 3, 2016
Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development
Ivan Gentile, Riccardo Scotto, Emanuela Zappulo, et al.
Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research
|
March 18, 2003
Pernicious anemia during IFN-alpha treatment for chronic hepatitis C
Guglielmo Borgia, Laura Reynaud, Ivan Gentile, et al.
Page
of 28